|
[1] HUANG S,YANG CL,ZHANG ZM. Research advances in targeted therapy for hepatocellular carcinoma[J]. J Clin Hepatol,2019,35(11):2573-2577.(in Chinese)黄燊，杨成雷，张志明．肝细胞癌的靶向治疗[J]．临床肝胆病杂志，2019,35(11):2573-2577.
|
|
[2] MOCAN T,SPARCHEZ Z,CRACIUN R,et al. Programmed cell death protein-1(PD-1)/programmed death-ligand-1(PD-L1)axis in hepatocellular carcinoma:Prognostic and therapeutic perspectives[J]. Clin Transl Oncol,2019,21(6):702-712.
|
|
[3] ZHANG C,CHEN LH. Advances in immunoregulation of PD-1/PD-L1 in hepatocellular carcinoma[J]. Modern Hosp,2017,17(6):849-851.(in Chinese)张弛，陈龙华．PD-1/PD-L1在肝细胞癌中免疫调节作用的研究进展[J]．现代医院，2017,17(6):849-851.
|
|
[4] CHEN Y,WANG Q,SHI B,et al. Development of a sandwich ELISA for evaluating soluble PD-L1(CD274)in human sera of different ages as well as supernatants of PD-L1+cell lines[J]. Cytokine,2011,56(2):231-238.
|
|
[5] ROSSILLE D,GRESSIER M,DAMOTTE D,et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma:Results from a French multicenter clinical trial[J]. Leukemia,2014,28(12):2367-2375.
|
|
[6] WANG L,WANG H,CHEN H,et al. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma[J]. Oncotarget,2015,6(38):41228-41236.
|
|
[7] PAN SY,WANG ZX,ZHOU Y,et al. Function and mechanism of action of the PD-1/PD-L1 pathway in liver diseases[J].J Clin Hepatol,2019,35(3):672-676.(in Chinese)潘思宇，王志鑫，周灜，等．PD-1/PD-L1信号通路在肝脏疾病中的功能及作用机制[J]．临床肝胆病杂志，2019,35(3):672-676.
|
|
[8] IWAI Y,HAMANISHI J,CHAMOTO K,et al. Cancer immunotherapies targeting the PD-1 signaling pathway[J]. J Biomed Sci,2017,24(1):26.
|
|
[9] GAO Q,WANG XY,QIU SJ,et al. Overexpression of PD-L1significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma[J]. Clin Cancer Res,2009,15(3):971-979.
|
|
[10] GU X,GAO XS,XIONG W,et al. Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients[J]. Onco Targets Ther,2016,9:4805-4813.
|
|
[11] WU K,KRYCZEK I,CHEN L,et al. Kupffer cell suppression of CD8+T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions[J]. Cancer Res,2009,69(20):8067-8075.
|
|
[12] ZENG Z,SHI F,ZHOU L,et al. Upregulation of circulating PDL1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma[J]. PLo S One,2011,6(9):e23621.
|
|
[13] KAN G,DONG W. The expression of PD-L1 APE1 and P53in hepatocellular carcinoma and its relationship to clinical pathology[J]. Eur Rev Med Pharmacol Sci,2015,19(16):3063-3071.
|
|
[14] UMEMOTO Y,OKANO S,MATSUMOTO Y,et al. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy[J]. J Gastroenterol,2015,50(1):65-75.
|
|
[15] FINKELMEIER F,CANLI，TAL A,et al. High levels of the soluble programmed death-ligand(s PD-L1)identify hepatocellular carcinoma patients with a poor prognosis[J]. Eur J Cancer,2016,59:152-159.
|
|
[16] GABRIELSON A,WU Y,WANG H,et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC[J]. Cancer Immunol Res,2016,4(5):419-430.
|
|
[17] JUNG HI,JEONG D,JI S,et al. Overexpression of PD-L1and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma[J]. Cancer Res Treat,2017,49(1):246-254.
|
|
[18] CALDERARO J,ROUSSEAU B,AMADDEO G,et al. Programmed death ligand 1 expression in hepatocellular carcinoma:Relationship with clinical and pathological features[J].Hepatology,2016,64(6):2038-2046.
|
|
[19] SEMAAN A,DIETRICH D,BERGHEIM D,et al. CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia[J]. Virchows Arch,2017,470(2):185-196.
|
|
[20] HU K,WANG ZM,LI JN,et al. CLEC1B expression and PDL1 expression predict clinical outcome in hepatocellular carcinoma with tumor hemorrhage[J]. Transl Oncol,2018,11(2):552-558.
|
|
[21] ZHONG JH,LUO CP,ZHANG CY,et al. Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients[J]. J Hepatocell Carcinoma,2017,4:11-13.
|
|
[22] WANG Q,LIU F,LIU L. Prognostic significance of PD-L1 in solid tumor:An updated meta-analysis[J]. Medicine(Baltimore),2017,96(18):e6369.
|
|
[23] PYO JS,KANG G,KIM JY. Prognostic role of PD-L1 in malignant solid tumors:A meta-analysis[J]. Int J Biol Markers,2017,32(1):e68-e74.
|
|
[24] LI JH,MA WJ,WANG GG,et al. Clinicopathologic significance and prognostic value of programmed cell death ligand 1(PD-L1)in Patients with hepatocellular carcinoma:A Metaanalysis[J]. Front Immunol,2018,9:2077.
|
|
[25] CHEN CL,PAN QZ,ZHAO JJ,et al. PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma[J]. Oncoimmunology,2016,5(7):e1176653.
|
|
[26] SIDERAS K,BIERMANN K,VERHEIJ J,et al. PD-L1,Galectin-9 and CD8+tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma[J]. Oncoimmunology,2017,6(2):e1273309.
|
|
[27] LIU GM,LI XG,ZHANG YM. Prognostic role of PD-L1 for HCC patients after potentially curative resection:A metaanalysis[J]. Cancer Cell Int,2019,19:22.
|
|
[28] COELHO MA,de CARNTRCESSON S,RANA S,et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA[J]. Immunity,2017,47(6):1083-1099. e6.
|
|
[29] TUMEH PC,HARVIEW CL,YEARLEY JH,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance[J]. Nature,2014,515(7528):568-571.
|
|
[30] RIBAS A,WOLCHOK JD. Cancer immunotherapy using checkpoint blockade[J]. Science,2018,359(6382):1350-1355.
|
|
[31] SCHUMACHER TN,SCHREIBER RD. Neoantigens in cancer immunotherapy[J]. Science,2015,348(6230):69-74.
|
|
[32] XIANG X,YU PC,LONG D,et al. Prognostic value of PDL1 expression in patients with primary solid tumors[J]. Oncotarget,2018,9(4):5058-5072.
|
|
[33] HUANG CY,WANG Y,LUO GY,et al. Relationship between PD-L1 expression and CD8+T-cell immune responses in hepatocellular carcinoma[J]. J Immunother,2017,40(9):323-333.
|
|
[34] SIMON I,ZHUO S,CORRAL L,et al. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer[J]. Cancer Res,2006,66(3):1570-1575.
|
|
[35] TAKAHASHI N,IWASA S,SASAKI Y,et al. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer[J].J Cancer Res Clin Oncol,2016,142(8):1727-1738.
|
|
[36] EL-GHAMMAZ A,GADALLAH HA,KAMAL G,et al. Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients[J]. Clin Exp Med,2018,18(4):505-512.
|
|
[37] AKUTSU Y,MURAKAMI K,KANO M,et al. The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma[J]. Esophagus,2018,15(2):103-108.
|
|
[38] EL-GEBALY F,ABOU-SAIF S,ELKADEEM M,et al. Study of serum soluble programmed death ligand 1 as a prognostic factor in hepatocellular carcinoma in egyptian patients[J].Curr Cancer Drug Targets,2019,19(11):896-905.
|
|
[39] KIM HJ,PARK S,KIM KJ,et al. Clinical significance of soluble programmed cell death ligand-1(sPD-L1)in hepatocellular carcinoma patients treated with radiotherapy[J]. Radiother Oncol,2018,129(1):130-135.
|
|
[40] HAN X,GU YK,LI SL,et al. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma[J]. J Cancer Res Clin Oncol,2019,145(2):303-312.
|
|
[41] BOMMARITO D,HALL C,TAAMS LS,et al. Inflammatory cytokines compromise programmed cell death-1(PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1[J]. Clin Exp Immunol,2017,188(3):455-466.
|
|
[42] CHANG B,HUANG T,WEI H,et al. The correlation and prognostic value of serum levels of soluble programmed death protein 1(s PD-1)and soluble programmed death-ligand 1(s PD-L1)in patients with hepatocellular carcinoma[J].Cancer Immunol Immunother,2019,68(3):353-363.
|
|
[43] ELMEZAYEN HA,OKABE H,BABA Y,et al. Clinical role of serum programmed death ligand 1 in patients with hepatocellular carcinoma:Where does it come from?[J]. Surg Today,2020,50(6):569-576.
|
|
[44] NISHIDA N,KUDO M. Liver damage related to immune checkpoint inhibitors[J]. Hepatol Int,2019,13(3):248-252.
|
DownLoad: